See more : BTS Group Holdings Public Company Limited (BTGRF) Income Statement Analysis – Financial Results
Complete financial analysis of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- NeuroBo Pharmaceuticals, Inc. (NRBO) Income Statement Analysis – Financial Results
- InterMetro Communications, Inc. (IMTO) Income Statement Analysis – Financial Results
- Strikewell Energy Corp. (SKKFF) Income Statement Analysis – Financial Results
- STL Global Limited (SGL.NS) Income Statement Analysis – Financial Results
- Global Star Acquisition, Inc. Class A Common Stock (GLST) Income Statement Analysis – Financial Results
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)
About BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.38M | 41.15M | 40.16M | 39.11M | 32.29M | 31.40M | 36.34M | 42.59M | 33.58M | 32.98M | 24.64M | 39.14M | 30.93M |
| Cost of Revenue | 22.45M | 18.49M | 19.59M | 17.85M | 16.14M | 17.36M | 23.03M | 34.71M | 17.77M | 5.98M | 1.11M | 9.86M | 7.03M |
| Gross Profit | 27.93M | 22.67M | 20.57M | 21.25M | 16.15M | 14.04M | 13.31M | 7.88M | 15.80M | 27.00M | 23.53M | 29.28M | 23.91M |
| Gross Profit Ratio | 55.44% | 55.08% | 51.21% | 54.35% | 50.02% | 44.71% | 36.62% | 18.49% | 47.07% | 81.87% | 95.50% | 74.80% | 77.29% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.73M | 12.30M | 13.87M | 11.39M | 11.89M | 12.89M | 11.84M | 9.21M | 8.27M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.39M | 2.58M | 1.80M | 3.99M | 4.10M | 5.05M | 5.37M | 7.36M | 3.84M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 14.88M | 15.67M | 15.38M | 15.99M | 17.94M | 17.21M | 16.57M | 12.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.56M | 1.23M | -1.57M | 78.00K | 65.00K | -1.07M | 2.39M | 24.56M | 669.89K | 21.91M | 29.55M | 25.82M | 25.70M |
| Operating Expenses | 18.68M | 16.11M | 14.10M | 15.45M | 16.06M | 16.86M | 19.60M | 41.13M | 12.79M | 21.91M | 29.55M | 25.82M | 25.70M |
| Cost & Expenses | 41.13M | 34.60M | 33.69M | 33.31M | 32.19M | 34.23M | 42.63M | 75.84M | 30.56M | 27.88M | 30.65M | 35.68M | 32.73M |
| Interest Income | 435.00K | 0.00 | 65.00K | 15.00K | 53.00K | 788.00K | 51.00K | 59.49K | 74.86K | 85.93K | 2.13M | 1.32M | 761.29K |
| Interest Expense | 1.61M | 1.28M | 1.65M | 2.02M | 2.83M | 3.96M | 3.70M | 6.57M | 2.44M | 2.28M | 2.62M | 2.98M | 1.89M |
| Depreciation & Amortization | 5.75M | 6.96M | 575.00K | 5.94M | -35.49M | 8.47M | 3.92M | 2.99M | 1.89M | 1.76M | 2.24M | 2.72M | 2.40M |
| EBITDA | 15.59M | 14.15M | 6.50M | 11.65M | -35.39M | 5.64M | -23.17M | -30.52M | 4.47M | 6.86M | -1.49M | 6.95M | 7.68M |
| EBITDA Ratio | 30.94% | 34.38% | 16.19% | 29.80% | -109.58% | 17.97% | -63.77% | -71.67% | 13.32% | 20.79% | -6.03% | 17.76% | 24.83% |
| Operating Income | 9.84M | 7.19M | 5.93M | 5.72M | 99.00K | -2.82M | -6.29M | -33.25M | 3.02M | 5.09M | -6.01M | 3.46M | -1.80M |
| Operating Income Ratio | 19.53% | 17.48% | 14.76% | 14.62% | 0.31% | -8.99% | -17.31% | -78.07% | 8.99% | 15.44% | -24.40% | 8.85% | -5.82% |
| Total Other Income/Expenses | -1.50M | -1.30M | -1.61M | -2.00M | -38.32M | 4.51M | -24.50M | -6.83M | -2.88M | -2.27M | -337.22K | -2.33M | 5.08M |
| Income Before Tax | 8.35M | 5.89M | 4.31M | 3.72M | -38.22M | 1.68M | -30.79M | -40.08M | 139.14K | 2.82M | -6.35M | 1.14M | 3.28M |
| Income Before Tax Ratio | 16.57% | 14.32% | 10.74% | 9.52% | -118.35% | 5.36% | -84.73% | -94.11% | 0.41% | 8.56% | -25.77% | 2.90% | 10.61% |
| Income Tax Expense | 2.27M | 1.64M | -126.00K | 1.24M | -5.81M | 1.09M | -7.31M | -2.84M | 24.07K | 485.98K | -1.04M | 726.93K | 850.84K |
| Net Income | 6.08M | 4.25M | 4.44M | 2.48M | -32.41M | 588.00K | -23.48M | -37.24M | 115.07K | 2.34M | -5.31M | 524.59K | 2.54M |
| Net Income Ratio | 12.07% | 10.32% | 11.05% | 6.35% | -100.37% | 1.87% | -64.60% | -87.45% | 0.34% | 7.09% | -21.55% | 1.34% | 8.21% |
| EPS | 0.09 | 0.07 | 0.07 | 0.04 | -0.56 | 0.01 | -0.53 | -0.84 | 0.00 | 0.06 | -0.14 | 0.01 | 0.08 |
| EPS Diluted | 0.09 | 0.07 | 0.07 | 0.04 | -0.56 | 0.01 | -0.53 | -0.84 | 0.00 | 0.06 | -0.14 | 0.01 | 0.08 |
| Weighted Avg Shares Out | 65.38M | 63.12M | 62.26M | 62.26M | 57.46M | 57.46M | 44.26M | 44.26M | 43.64M | 38.56M | 38.56M | 38.56M | 31.76M |
| Weighted Avg Shares Out (Dil) | 65.38M | 63.12M | 62.26M | 62.26M | 57.46M | 57.46M | 44.26M | 44.26M | 43.64M | 38.56M | 38.56M | 38.56M | 31.76M |
Source: https://incomestatements.info
Category: Stock Reports